See What HealthDay Can Do For You
Contact Us

ACAAI: Novel Immunotherapy Found Safe, Effective

Promise seen for allergen-independent immunostimulatory CpG oligonucleotide G10

MONDAY, Nov. 10 (HealthDay News) -- CYT003-QbG10 -- a novel allergen-independent immunotherapeutic consisting of a virus-like particle loaded with the immunostimulatory CpG oligonucleotide G10 agent -- may be a safe and effective treatment for a broad range of allergic diseases, according to research presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting held Nov. 6 to 11 in Seattle.

In a phase II study, Audra Blaziene, M.D., of Vilnius University in Lithuania, and colleagues randomly assigned 80 patients with mild-to-moderate perennial allergic rhinoconjunctivitis caused by dust mites and/or cat dander to receive six weekly injections of either CYT003-QbG10 or placebo.

Compared to placebo, the researchers found that CYT003-QbG10 was associated with a significant reduction of daily rhinoconjunctivitis symptoms and increased allergen tolerance as measured by a conjunctival provocation test.

"This opens a new avenue for a disease-modifying and allergen-independent therapy able to address multiple allergies," the authors conclude.

More Information

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.